PURPOSE: To evaluate the test-retest reliability of a device that measures urinary sensation during cystometry, and to use that device to determine whether treatment of overactive bladder syndrome (OAB) with solifenacin is associated with a change in urinary sensation. METHODS: Overall 15 women were recruited for this study, ten women with OAB and urodynamically demonstrated detrusor overactivity and five controls without OAB underwent filling cystometry twice with contemporaneous, continuous recording of urinary sensation. Women with OAB received solifenacin 10 mg daily during the weeks between testing. We compared the areas under the initial and repeat sensation-volume curves. RESULTS: While taking solifenacin, the maximum cystometric capacity increased from 329 ± 168 ml to 464 ± 123 ml (P < 0.002), and the area under the bladder volume-sensation curve decreased (P < 0.0001). Untreated controls did not exhibit these changes. CONCLUSION: We present psychometric data demonstrating improved bladder sensation during the treatment of OAB with solifenacin. If clinical correlations are confirmed by future study, such urinary sensation measures may prove useful as assessment, treatment predictor, or outcome measures in OAB research and/or clinical care.
PURPOSE: To evaluate the test-retest reliability of a device that measures urinary sensation during cystometry, and to use that device to determine whether treatment of overactive bladder syndrome (OAB) with solifenacin is associated with a change in urinary sensation. METHODS: Overall 15 women were recruited for this study, ten women with OAB and urodynamically demonstrated detrusor overactivity and five controls without OAB underwent filling cystometry twice with contemporaneous, continuous recording of urinary sensation. Women with OAB received solifenacin 10 mg daily during the weeks between testing. We compared the areas under the initial and repeat sensation-volume curves. RESULTS: While taking solifenacin, the maximum cystometric capacity increased from 329 ± 168 ml to 464 ± 123 ml (P < 0.002), and the area under the bladder volume-sensation curve decreased (P < 0.0001). Untreated controls did not exhibit these changes. CONCLUSION: We present psychometric data demonstrating improved bladder sensation during the treatment of OAB with solifenacin. If clinical correlations are confirmed by future study, such urinary sensation measures may prove useful as assessment, treatment predictor, or outcome measures in OAB research and/or clinical care.
Authors: Paul Abrams; Karl-Erik Andersson; Jerry J Buccafusco; Christopher Chapple; William Chet de Groat; Alison D Fryer; Gary Kay; Alan Laties; Neil M Nathanson; Pankaj Jay Pasricha; Alan J Wein Journal: Br J Pharmacol Date: 2006-06-05 Impact factor: 8.739
Authors: Bernard T Haylen; Dirk de Ridder; Robert M Freeman; Steven E Swift; Bary Berghmans; Joseph Lee; Ash Monga; Eckhard Petri; Diaa E Rizk; Peter K Sand; Gabriel N Schaer Journal: Int Urogynecol J Date: 2009-11-25 Impact factor: 2.894
Authors: Lior Lowenstein; Mary P FitzGerald; Kimberly Kenton; Linda Brubaker; Ilan Gruenwald; Irena Papier; Ramón A Durazo-Arvizu; Christina Elliot; Elizabeth R Mueller; Yoram Vardi Journal: Am J Obstet Gynecol Date: 2008-04-02 Impact factor: 8.661
Authors: Jonathan L Gleason; Kimberly Kenton; W Jerod Greer; Olga Ramm; Jeff M Szychowski; Tracey Wilson; Holly E Richter Journal: Neurourol Urodyn Date: 2012-11-20 Impact factor: 2.696
Authors: Karin S Coyne; Chris C Sexton; Christine Thompson; Tamara Bavendam; Linda Brubaker Journal: Int Urogynecol J Date: 2014-06-19 Impact factor: 2.894